CARDIO-TTRansform unexpectedly underperforms, with pressure on IONS and an improved competitive picture for ALNY

Overview

This report focuses on the impact of AZN/IONS ASO drug Wainua unexpectedly failing to meet the primary endpoint in the ATTR-cardiomyopathy phase 3 CARDIO-TTRansform study. The miss is largely driven by the lack of observed treatment effect in patients with baseline stabilizer background therapy, while outcomes in patients receiving tafamidis were better than expected. The report views this as a negative event for IONS and removes Wainua's ATTR-CM contribution from the model; for ALNY the impact is relatively positive because competitive pressure on its siRNA therapy Amvuttra and next-generation asset nucresiran appears to have declined.

Core views

The key message is: first, the failure of CARDIO-TTRansform changed the previously anticipated success narrative, especially because the background stabilizer-treated population did not reach significance; second, IONS' near-term focus will shift to severe hypertriglyceridemia, particularly ARWR's quarterly phase 3 SHTG data relative to IONS Tryngolza positioning; third, ALNY's competitive narrative in ATTR-CM improved marginally, but the market still needs to analyze the full August ESC Congress data to assess implications for future silencing agents and combination therapy designs with stabilizers.

Analysis framework

The report uses event-driven clinical data interpretation, cross-ATTR-CM trial design comparison, valuation model adjustment and a risk-adjusted DCF valuation framework. Analysis highlights include primary endpoint results, pre-specified subgroups, baseline stabilizer background therapy share, baseline disease severity, sample size and statistical assumptions, and compares CARDIO-TTRansform with HELIOS-B and ALNY's upcoming TRITON-CM study.

Methodology notes

• Valuation methods风险调整DCF

  Target price estimation

  The 12-month target price for IONS is $68, based on risk-adjusted DCF, a 13% WACC and a 3% terminal growth rate; ALNY's 12-month target price is $550, 100% based on risk-adjusted DCF, a 9% WACC and a 3.5% terminal growth rate.

• Factor analysisGS Factor Profile

  Growth, financial returns, valuation multiples, and composite percentile

  The Goldman Sachs Factor Profile compares each stock with the market and industry peers using growth, financial returns, valuation multiples, and a composite indicator, to provide investment context.

• M&A scenariosM&A Rank

  Potential takeout probability ranking

  Goldman Sachs uses a 1-to-3 scale M&A rank to assess the probability that a company could become an acquisition target, with 1 representing high probability, 2 medium, and 3 low.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Ionis Pharmaceuticals Inc. (IONS)

  Most directly affected company; Wainua is an AZN/IONS co-developed ASO asset

  Strengths

  The prespecified monotherapy subgroup showed nominally significant HR 0.71, and IONS still has other pipeline assets such as Tryngolza for the market to reassess.

  Weaknesses

  CARDIO-TTRansform did not meet the primary endpoint; patients with background stabilizer therapy did not show benefit; Wainua ATTR-CM model contribution was removed.

  Comparison

  Compared with ALNY, IONS' competitive position in ATTR-CM has weakened markedly; compared with ARWR, near-term focus shifts to how SHTG phase 3 data compare for Tryngolza.

  Risks

  Clinical failure, regulatory and reimbursement uncertainty, commercialization below expectations, competitors progressing faster or with better data, and intellectual property or financial risks.

• Alnylam Pharmaceuticals Inc. (ALNY)

  Indirect beneficiary with reduced ATTR-CM competitive set

  Strengths

  Goldman Sachs maintained Buy; competitive pressure on Amvuttra eased, and the TRITON-CM study of next-generation nucresiran continues.

  Weaknesses

  Future nucresiran still needs to validate efficacy in patients on background stabilizer treatment, and the ATTR-CM competitive landscape remains affected by other medicines and treatment paradigms.

  Comparison

  Relative to IONS, ALNY has a more favorable ATTR-CM competitive narrative after this event.

  Risks

  Clinical or technical failure, superior competing data, new modalities such as gene therapy changing treatment paradigms, and reimbursement or regulatory approval setbacks in U.S. and international commercialization.

• AstraZeneca (AZN)

  Wainua partner and participant in CARDIO-TTRansform development

  Strengths

  Continuing analysis of full data with IONS and planned disclosure at ESC.

  Weaknesses

  Wainua failed to meet the phase 3 primary endpoint in ATTR-CM, and the benefit of combination therapy with stabilizers is lacking.

  Comparison

  In ATTR-CM silencing-agent competition, AZN is temporarily behind market-accepted or more clearly path-cleared competing approaches.

  Risks

  Full data could further confirm no benefit with combination therapy, affecting future indication decisions and development strategy.

Key data

• CARDIO-TTRansform sample sizen=1,432The report states this is the largest fully enrolled ATTR-CM trial to date.
• Primary endpointMissedThe primary endpoint was the composite of cardiovascular death and recurrent cardiovascular clinical events through Week 140.
• Wainua monotherapy subgroupHR 0.71The prespecified monotherapy subgroup achieved nominal significance, but this was insufficient to offset the lack of efficacy in the stabilizer background population.
• Baseline TTR stabilizer use57%An additional 24% of patients initiated stabilizer therapy during the trial.
• SGLT2 inhibitor use18%Above the 3% observed in HELIOS-B.
• NYHA Class III share17%Higher than the 9% in HELIOS-B, suggesting the enrolled population may be sicker.
• IONS target price adjustment$68, previous $75Goldman Sachs removed Wainua ATTR-CM from the IONS model.
• ALNY target price$550Goldman Sachs maintained a Buy rating, with valuation based on risk-adjusted DCF.
• Full data disclosure timeAugust 2026 ESC CongressIONS and AZN plan to release full data at the European Society of Cardiology Congress.

Impact & implications

The immediate impact on IONS is weaker commercialization assumptions for ATTR-CM, with Wainua removed from this indication in valuation and a lower target price. The impact on ALNY is relatively positive, as the withdrawal or weakening of a potential competitor improves Amvuttra's competitive position in ATTR-CM. However, the full data disclosure may still influence the market's view on combined silencing-plus-stabilizer treatment, future TRITON-CM design for nucresiran, and endpoint selection.

Risks

• Full CARDIO-TTRansform data have not yet been disclosed; results at the August ESC Congress may change interpretation of subgroups and trial design.
• The ATTR-CM treatment landscape is jointly influenced by tafamidis, Attruby, Amvuttra, Wainua, and next-generation silencing agents, so competitive pathways remain uncertain.
• IONS faces clinical, regulatory, reimbursement, commercialization, and competing pipeline advancement risks.
• Although ALNY benefits from reduced competitors, it still faces risks of clinical failure for nucresiran, better competing data, and new treatment paradigms.
• Goldman Sachs has disclosed investment banking, market-making, and other business relationships with ALNY and IONS, and investors should read these through the lens of conflicts disclosures.

What to watch

• Full CARDIO-TTRansform data to be disclosed at the 2026 August ESC Congress.
• Interpretability of efficacy differences between background stabilizer-treated patients and monotherapy patients.
• ARWR quarterly SHTG phase 3 data and product profile relative to IONS Tryngolza.
• Event-driven results of nucresiran in ALNY's TRITON-CM study under background stabilizer treatment.
• How IONS further updates revenue, EPS, and pipeline value assumptions after removing Wainua ATTR-CM.